Am I eligible for Mounjaro on the NHS? The criteria explained

The biggest misconception: why a high BMI alone is not enough

The question our prescribers hear most often is some version of: "My BMI is 42, surely I qualify?" The honest answer is that NICE's recommendation for Mounjaro (TA1026, published December 2024 and updated September 2025) ties access to a combination of BMI and comorbidities, not BMI in isolation. The five qualifying conditions are high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. You need to have at least four of them (alongside the relevant BMI threshold) to meet the current NHS criteria.

That catches a lot of people off guard. Someone with a BMI of 44 and two of those conditions does not qualify yet. Someone with a BMI of 36 and four conditions now does, since Cohort 2 opened in June 2026. The NHS is deliberately phasing rollout to reach the people with the highest clinical need first, then broadening access over time. It is a reasonable public-health decision, but it means the waiting is real for many people who would benefit.

One practical check you can do right now: count the conditions on that list of five that appear in your NHS record. If you are not sure whether a diagnosis is recorded, your GP surgery can usually confirm in a short call. That takes less than a minute and tells you immediately which cohort, if any, you currently fall into.

The NHS phased rollout, what each cohort actually means

Cohort 1 opened in June 2025 for adults with a BMI of 40 or above plus four or more of the five qualifying conditions. From 23 June 2026, Cohort 2 extended access to adults with a BMI between 35 and 39.9 who also have four or more of those conditions. A further phase, expected around March 2027, will lower the comorbidity requirement to three conditions at BMI 40 or above.

From 1 April 2026, GP practices gained the ability to prescribe Mounjaro under the new GP contract, but participation is optional. Whether your surgery has joined the scheme varies by practice and area. If yours has not, you may still be referred to a specialist weight management service, but waiting times through that route are commonly long. You can find more detail on how the NHS pathway works on our Mounjaro and the NHS page.

Ethnic-background adjustments reduce each BMI threshold by 2.5 kg/m². So for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the Cohort 1 threshold becomes BMI 37.5, and Cohort 2 becomes 32.5 to 37.4. NICE built this in to reflect the different metabolic risk profiles at equivalent BMIs. For a more detailed breakdown of how those adjustments interact with each cohort, the NHS Mounjaro BMI guide covers it step by step.

What happens if you meet the criteria but cannot get it through your GP yet

Even meeting the cohort criteria does not guarantee a prescription. Your GP practice has to be participating in the scheme, stock has to be available through the NHS supply, and you have to engage with the "wraparound" diet and activity support that NICE requires alongside treatment. If your practice is not yet on board, or if the waiting list at your local specialist service stretches months ahead, you may be in the criteria on paper but nowhere close to treatment in practice.

This is where private prescription routes become relevant. A private Mounjaro prescription through a GPhC-registered pharmacy does not require a referral, does not depend on your GP's participation in any NHS scheme, and does not have a waiting list. The clinical bar is set by the licensed eligibility criteria in the Mounjaro SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That is a meaningfully broader group than the current NHS cohorts.

It is still a prescription-only medicine. A named clinician, not an automated system, reviews every consultation before anything is issued. Cost context is worth understanding too, our Mounjaro pricing page sets out what private treatment typically involves. But for people who would benefit now and cannot access the NHS route, a regulated private pharmacy is the legal alternative. Worth exploring if you are tired of waiting.

When NHS criteria will not apply, and what the private route looks like

If you do not currently have four qualifying comorbidities, or your BMI sits below the relevant cohort threshold, the NHS route is closed for now regardless of how much weight you carry or how much it is affecting your life. That is not a reflection of whether treatment would help you, it is a rationing decision. NICE and NHS England have been clear about that.

The private licensed criteria are different. Tirzepatide is licensed in the UK for weight management in adults with a BMI of 30 or above, or BMI 27 or above alongside a weight-related health condition such as prediabetes, raised blood pressure, high cholesterol, or obstructive sleep apnoea. Under those criteria, far more people are clinically suitable. Our clinical team at nume reviews every case individually; there is no automatic approval, and prescribers look at the full picture. More detail on who is clinically suitable privately is on our eligibility comparison page. If you want to understand how to make the most of treatment once you do start, the Mounjaro results guide is worth reading alongside this. The Mounjaro treatment overview has the full picture in one place. For a broader look at weight management options, our weight-loss page covers what is currently available.